Mohammed Elsalanty

Mohammed Elsalanty

Auto-generated profile, based on publicly available information

Mohammed Elsalanty

Western University of Health Sciences

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2019 in Journal of Cranio-Maxillofacial Surgery
Verified
Journal Article
Closed access
MAMohamed E. Awad
Mohamed E. Awad
AAAmara Altman
Amara Altman
RERadwa Elrefai
Radwa Elrefai
PSPeter Shipman
Peter Shipman
SLStephen Looney
Stephen Looney
MEMohammed Elsalanty
Mohammed Elsalanty

1 October 2018 in Bone
Verified
Journal Article
Closed access
KDKe-Hong Ding
Ke-Hong Ding
MCMichael Cain
Michael Cain
MDMichael Davis
Michael Davis
CBClare Bergson
Clare Bergson
MMMeghan McGee-Lawrence
Meghan McGee-Lawrence
CICarlos Isales
Carlos Isales

9 January 2020 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
RERanya Elsayed
Ranya Elsayed
ZKZoya Kurago
Zoya Kurago
CCChristopher W. Cutler
Christopher W. Cutler
RARoger M. Arce
Roger M. Arce
JGJennifer Gerber
Jennifer Gerber
MEMohammed E. Elsalanty
Mohammed E. Elsalanty
Dendritic cells are an important link between innate and adaptive immune response. The role of dendritic cells in bone homeostasis, however, is not understood. Osteoporosis medications that inhibit osteoclasts have been associated with osteonecrosis, a condition limited to the jawbone, thus called medication‐related osteonecrosis of the jaw. We propose that disruption of the local immune response renders the oral microenvironment conducive to osteonecrosis. We tested whether zoledronate (Zol) treatment impaired dendritic cell (DC) functions and increased bacterial load in alveolar bone in vivo and whether DC inhibition alone predisposed the animals to osteonecrosis. We also analyzed the role of Zol in impairment of differentiation and function of migratory and tissue‐resident DCs, promoting disruption of T‐cell activation in vitro. Results demonstrated a Zol induced impairment in DC functions and an increased bacterial load in the oral cavity. DC‐deficient mice were predisposed to osteonecrosis following dental extraction. Zol treatment of DCs in vitro caused an impairment in immune functions including differentiation, maturation, migration, antigen presentation, and T‐cell activation. We conclude that the mechanism of Zol‐induced osteonecrosis of the jaw involves disruption of DC immune functions required to clear bacterial infection and activate T cell effector response.

17 July 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
RHR Nicole Howie
R Nicole Howie
JBJames L Borke
James L Borke
ZKZoya Kurago
Zoya Kurago
ADAsma Daoudi
Asma Daoudi
JCJames Cray
James Cray
MEMohammed E Elsalanty
Mohammed E Elsalanty
This study aims to develop a reproducible rat model for post-traumatic bisphosphonate-related osteonecrosis of the jaw (BRONJ). In our previous studies using dental extraction as an inducing factor, only 30% - 60% of zoledronate-treated animals fulfilled the definition of clinical BRONJ. We modified the zoledronate regimen and introduced repeated surgical extraction to illicit quantifiable BRONJ in all animals. Eighty retired-breeder female Sprague-Dawley rats were divided between the treatment (IV zoledronate; 80 μg/kg/week for 13 weeks) and control (saline) groups. On week 13, the left mandibular first molar was surgically extracted, followed by the second molar a week later. Animals were euthanized at 1-week, 2-weeks, and 8-weeks following extraction. The occurrence and severity of BRONJ were scored in each animal based on gross and MicroCT analysis. Parameters of bone formation and osteoclast functions at the extraction site were compared between groups. All zoledronate-treated animals developed a severe case of BRONJ that fulfilled the clinical definition of the condition in humans. Osteoclast attachment continued to be defective eight weeks after stopping the treatment. There were no signs of kidney or liver toxicity. Our data confirmed that repeated surgical extraction (major trauma) by itself consistently precipitated massive bone necrosis in ZA-treated animals, eliminating the need to induce pre-existing infection or comorbidity. These results will be the basis for further studies examining the in-vivo pathogenesis and prevention of BRONJ.

24 January 2019 in EPMA Journal
Verified
Journal Article
Closed access
PDF file
MSMartin Salgueiro
Martin Salgueiro
MSMichael Stribos
Michael Stribos
LZLi Fang Zhang
Li Fang Zhang
MSMark Stevens
Mark Stevens
MAMohamed E. Awad
Mohamed E. Awad
MEMohammed Elsalanty
Mohammed Elsalanty

17 January 2019 in Cells
Verified
Journal Article
Open access
PDF file
QSQuante Singleton
Quante Singleton
Kumar VaibhavKumar Vaibhav
Kumar Vaibhav
MBMolly Braun
Molly Braun
CPChandani Patel
Chandani Patel
AKAndrew Khayrullin
Andrew Khayrullin
SFSadanand Fulzele
Sadanand Fulzele
Traumatic brain injury (TBI) is a major source of worldwide morbidity and mortality. Patients suffering from TBI exhibit a higher susceptibility to bone loss and an increased rate of bone fractures; however, the underlying mechanisms remain poorly defined. Herein, we observed significantly lower bone quality and elevated levels of inflammation in bone and bone marrow niche after controlled cortical impact-induced TBI in in vivo CD-1 mice. Further, we identified dysregulated NF-κB signaling, an established mediator of osteoclast differentiation and bone loss, within the bone marrow niche of TBI mice. Ex vivo studies revealed increased osteoclast differentiation in bone marrow-derived cells from TBI mice, as compared to sham injured mice. We also found bone marrow derived extracellular vesicles (EVs) from TBI mice enhanced the colony forming ability and osteoclast differentiation efficacy and activated NF-κB signaling genes in bone marrow-derived cells. Additionally, we showed that miRNA-1224 up-regulated in bone marrow-derived EVs cargo of TBI. Taken together, we provide evidence that TBI-induced inflammatory stress on bone and the bone marrow niche may activate NF-κB leading to accelerated bone loss. Targeted inhibition of these signaling pathways may reverse TBI-induced bone loss and reduce fracture rates.